Business Risk Intelligence for Pharmaceuticals
Pharmaceutical companies invest billions of dollars and years of research into discovering and developing new drugs. Since their intellectual property is some of the most valuable across all industries, it can be an attractive target for a range of adversaries.
In response, pharmaceutical leaders are turning to Business Risk Intelligence (BRI) to gain a decision advantage over these adversaries.
The use cases within this report address:
• Intellectual Property Theft
• Third-Party Risk
• Underground Drug Trafficking
• Incident Response
To learn more, download the report.